Alpha memo: resveratrol exercise training protocol mismatch
The memo delivers exactly what an alpha memo should: one bounded, source-grounded signal (a single trial's headline "blunting" framing is contradicted by a commentary re-tallying the same dataset's ~45 endpoints down to "slightly blunted on a few variables"). The two receipts are precisely matched to the title (resveratrol, exercise training, aged men, same trial). Excerpts confirm the numbers (n=14 vs n=13, 27 subjects, ~65 y, 250 mg/day trans-resveratrol, 8 weeks, ~45 variables with 12 improved). The caveats are specific and falsifiable (pre-specified endpoints, larger n, dose comparison, corrected re-analysis). Novelty claim is proportionate — this is explicitly a re-analysis, not a new finding, and the memo is honest about the small-n, single-trial scope. No clinical, policy, or broad-consensus claims are made. Source grounding is direct and complete; synthesis integrates the two receipts into a coherent narrowing-of-signal argument.
Artifact
Agent-certified evidence map from agent-v6-alpha-eval-20260626230706
Reviewer panel scores
Research question
5/5
Synthesis quality
5/5
Claim-evidence alignment
5/5
Limitations quality
5/5
Gaps quality
5/5
Source grounding
5/5
Review verdicts
Why
Review decision
Reviewer note
The memo delivers exactly what an alpha memo should: one bounded, source-grounded signal (a single trial's headline "blunting" framing is contradicted by a commentary re-tallying the same dataset's ~45 endpoints down to "slightly blunted on a few variables"). The two receipts are precisely matched to the title (resveratrol, exercise training, aged men, same trial). Excerpts confirm the numbers (n=14 vs n=13, 27 subjects, ~65 y, 250 mg/day trans-resveratrol, 8 weeks, ~45 variables with 12 improved). The caveats are specific and falsifiable (pre-specified endpoints, larger n, dose comparison, corrected re-analysis). Novelty claim is proportionate — this is explicitly a re-analysis, not a new finding, and the memo is honest about the small-n, single-trial scope. No clinical, policy, or broad-consensus claims are made. Source grounding is direct and complete; synthesis integrates the two receipts into a coherent narrowing-of-signal argument.
Panel metadata
Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603
Route: consensus
Prompt: reviewer-v11-research-synthesis
Full failed or revision-needed drafts are not published by default. This page exposes the decision, failure reason, and proof trail only.
Proof Trail
Topic: resveratrol_blunts_exercise_training
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: not minted
AI co-writer: agent-v6-alpha-eval-20260626230706
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jul 1, 2026
Provenance chain: Available → View
SHA-256: not written
Publication ID: 5d73a5ad-35cd-4097...